reports
Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data...
JP Jenkins Ltd Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers 28-Jun-2024 / 10:39 GMT/BST The issuer is solely responsible for the content of this announcement. 28th June 2024 ISIN: GB00BSNB6S51JPJ:REDX REDX PHARMA LIMITED ("Redx" or the “Company") Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers Zamaporvint in combination with a...
Smith+Nephew takes centre court sponsoring players competing at Wimble...
Smith+Nephew takes centre court sponsoring players competing at Wimbledon; global Sports Medicine technology leader helping athletes get back in the game Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will sponsor tennis players participating in The Championships, Wimbledon 2024 to spotlight its advanced Sports Medicine portfolio alongside some of the greatest athletes in the world. Smith+Nephew endeavours to help people live their ‘Life Unlimited’ by aiding in their recovery from injury and get them back to doing what they love. ...
- Farid Bitari
- Ghada Ben Sedrine
- Nicolas David
- Stephane Houri
ODDO : Generative AI: a genuine revolution, pending the next revolutio...
Our conviction on the long-term growth potential and opportunities of generative AI is renewed. The enabler sectors (semiconductors, software and IT services) and those that provide the infrastructure (utilities, metals, capital goods and real estate) will be the primary beneficiaries, leading us to make certain target price changes. Among AI ‘user’ sectors (media, healthcare, automotive, banking and insurance, oil services, defence, aerospace and airlines), the effects will doub...
LR LEGRAND SA
BMW BAYERISCHE MOTOREN WERKE AG
REL RELX PLC
PUB PUBLICIS GROUPE SA
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
AAL ANGLO AMERICAN PLC
SU SCHNEIDER ELECTRIC SE
SOP SOPRA STERIA GROUP SA
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
INF INFOTEL SA
GLE SOCIETE GENERALE S.A. CLASS A
NOKIA NOKIA OYJ
TEP TELEPERFORMANCE SE
WKL WOLTERS KLUWER NV
AUB AUBAY SA
MRK MERCK KGAA
ALTA ALTAREA SCA
ATE ALTEN SA
RWE RWE AG
SAN SANOFI
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
ENEL ENEL SPA
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
ICAD ICADE SA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
TIETO TIETOEVRY OYJ
NDA AURUBIS AG
NEM NEMETSCHEK SE
AMS AMADEUS IT GROUP SA CLASS A
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
PRY PRYSMIAN S.P.A.
IBE IBERDROLA SA
OREGE OREGE SA
SMHN SUESS MICROTEC AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
VACN VAT GROUP AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
IDR INDRA SISTEMAS S.A. CLASS A
RIO RIO TINTO PLC
SAP SAP SE
AZN ASTRAZENECA PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
REY REPLY S.P.A.
STM STMICROELECTRONICS NV
SHL SIEMENS HEALTHINEERS AG
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
WAVE WAVESTONE SA
GRE GRENERGY RENOVABLES
STLA STELLANTIS N.V.
DSY DASSAULT SYSTEMES SA
OVH OVH GROUPE
ATCO A ATLAS COPCO AB
IOS IONOS GROUP SE
ARM ARM HOLDINGS PLC
UN0 UNIPER SE
- Farid Bitari
- Ghada Ben Sedrine
- Nicolas David
- Stephane Houri
ODDO : L’IA générative, une véritable révolution, en attendant la proc...
Notre conviction sur le potentiel de croissance LT et d’opportunités de l’IA générative est renforcée. Les secteurs 'enablers' (semiconducteurs, software et IT services) et fournisseurs d’infrastructures (utilities, métaux, biens d'équipements et immobilier) en seront les premiers bénéficiaires, conduisant à certains changements d’OC. Parmi les secteurs ‘utilisateurs’ de l’IA (média, santé, automobile, banque et assurance, services pétroliers, défense, aéronautique et compagnies ...
LR LEGRAND SA
BMW BAYERISCHE MOTOREN WERKE AG
REL RELX PLC
PUB PUBLICIS GROUPE SA
VIE VEOLIA ENVIRONNEMENT SA
ENGI ENGIE SA.
EDP EDP-ENERGIAS DE PORTUGAL SA
AAL ANGLO AMERICAN PLC
SU SCHNEIDER ELECTRIC SE
SOP SOPRA STERIA GROUP SA
BNP BNP PARIBAS SA CLASS A
RNO RENAULT SA
ACN ACCENTURE PLC CLASS A
NOVN NOVARTIS AG
FORTUM FORTUM OYJ
DAI DAIMLER AG
ERIC B TELEFONAKTIEBOLAGET LM ERICSSON CLASS B
INF INFOTEL SA
GLE SOCIETE GENERALE S.A. CLASS A
NOKIA NOKIA OYJ
TEP TELEPERFORMANCE SE
WKL WOLTERS KLUWER NV
AUB AUBAY SA
MRK MERCK KGAA
ALTA ALTAREA SCA
ATE ALTEN SA
RWE RWE AG
SAN SANOFI
NEX NEXANS SA
VOW3 VOLKSWAGEN AG PREF
CAP CAPGEMINI SE
ENEL ENEL SPA
DTE DEUTSCHE TELEKOM AG
WPP WPP PLC
ICAD ICADE SA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
TIETO TIETOEVRY OYJ
NDA AURUBIS AG
NEM NEMETSCHEK SE
AMS AMADEUS IT GROUP SA CLASS A
INW INFRASTRUTTURE WIRELESS ITALIANE S.P.A.
PRY PRYSMIAN S.P.A.
IBE IBERDROLA SA
OREGE OREGE SA
SMHN SUESS MICROTEC AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
CLNX CELLNEX TELECOM S.A.
VACN VAT GROUP AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
IDR INDRA SISTEMAS S.A. CLASS A
RIO RIO TINTO PLC
SAP SAP SE
AZN ASTRAZENECA PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
ASML ASML HOLDING NV
REY REPLY S.P.A.
STM STMICROELECTRONICS NV
SHL SIEMENS HEALTHINEERS AG
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
WAVE WAVESTONE SA
GRE GRENERGY RENOVABLES
STLA STELLANTIS N.V.
DSY DASSAULT SYSTEMES SA
OVH OVH GROUPE
ATCO A ATLAS COPCO AB
IOS IONOS GROUP SE
ARM ARM HOLDINGS PLC
UN0 UNIPER SE
- Martin Hall
Hardman & Co Insight: Survival of the UK life sciences sector
For two years running, the Hardman & Co Healthcare index has declined, underperforming both the FTSE 100 and the FTSE All-Share indices. This is quite unusual for healthcare stocks. Apart from the general economic influences, which have made institutions more risk-averse, there was a common knowledge that several companies were in need of additional working capital; so, share prices were marked down in anticipation of equity raises. However, the small- and mid-cap life sciences sector has alway...
ETX E-THERAPEUTICS
AGY ALLERGY THERAPEUTICS PLC
AVO ADVANCED ONCOTHERAPY
YGEN YOURGENE HEALTH
ALNOV NOVACYT SAS
C4XD C4X DISCOVERY HOLDINGS
REDX REDX PHARMA
GDR GENEDRIVE
GSK GLAXOSMITHKLINE PLC
AZN ASTRAZENECA PLC
CTEC CONVATEC GROUP PLC
RENE RENEURON GROUP
0008964D INDIVIOR INC
IMCR IMMUNOCORE HOLDINGS ADS
ONT OXFORD NANOPORE TECHNOLOGIES PLC
SLN SILENCE THERAPEUTICS PLC
TRX TISSUE REGENIX GROUP PLC
GSK: 11 directors
Eleven Directors at GSK bought/gave away 382,360 shares at between 0.000USD and 16.145USD. The significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Immunocore announces randomization of first patient in the global, reg...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma The Phase 3 PRISM-MEL-301 trial will study the efficacy and safety of brenetafusp (IMC-F106C; PRAME-A02) in combination with nivolumab versus nivolumab or nivolumab + relatlimab in first-line advanc...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
NUE NUCOR CORPORATION
CNHI CNH INDUSTRIAL NV
WDAY WORKDAY INC. CLASS A
VALE.N VALE S.A. ADS
UEC URANIUM ENERGY CORP
TX. TERNIUM S.A. SPONSORED ADR
TWI TITAN INTERNATIONAL INC.
SYY SYSCO CORPORATION
RGEN REPLIGEN CORPORATION
POOL POOL CORPORATION
LEA LEAR CORPORATION
JNJ JOHNSON & JOHNSON
HSIC HENRY SCHEIN INC.
GIS GENERAL MILLS INC.
EXAS EXACT SCIENCES CORPORATION
DIN DINE BRANDS GLOBAL INC.
BRKR BRUKER CORPORATION
BAX BAXTER INTERNATIONAL INC.
CF. CANACCORD GENUITY GROUP
MG/CN MAGNA INTERNATIONAL INC.
SIBN GAZPROM NEFT PJSC
AMWD AMERICAN WOODMARK CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
CEXA CEMEX SAB DE CV (ADR)
DRI DARDEN RESTAURANTS INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
SSD SIMPSON MANUFACTURING CO. INC.
YUMC YUM CHINA HOLDINGS INC.
MT ARCELORMITTAL
ASGN ASGN INC
ADNT ADIENT PLC
PTAL PETROTAL
GNMSY GENMAB A/S
ORIC ORIC PHARMACEUTICALS
IMCR IMMUNOCORE HOLDINGS ADS
OI O-I GLASS INC
ENOV ENOVIS CORPORATION
WMC WESTMOUNT MINERALS CORP
Smith+Nephew personalizes robotic-assisted surgery for patients and su...
Smith+Nephew personalizes robotic-assisted surgery for patients and surgeons with launch of CORIOGRAPH™ Pre-Operative Planning and Modeling Services exclusively for the CORI™ Surgical System Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new CORIOGRAPH Pre-Operative Planning and Modeling Services, providing an unparalleled, personalized solution for surgeons and patients across partial and total knee arthroplasty procedures. It is exclusively for use with the CORI Surgical System - the only orthopaedic robotic-assisted system to off...
- Team Pharma
ODDO : ASCO 2024 expert access feedback
>Four types of treatment stand out - On Monday, we had the pleasure of hosting Dr Stéphane Champiat, oncologist at Gustave Roussy hospital (Paris), for our Expert Access on the ASCO 2024 with a focus on early-stage developments in solid tumours. His presentation confirmed that immunotherapy and chemotherapy remain the therapeutic backbone of cancer treatment, and also highlighted four promising treatments: T-cell engagers, cell therapies, immune checkpoint inhibitors...
- Team Pharma
ODDO : Feedback Expert Access ASCO 2024
>Quatre modalités de traitement ressortent du lot - Nous avons eu le plaisir d’accueillir lundi le Dr. Stéphane Champiat, médecin oncologue au sein de l’hôpital Gustave Roussy (Paris) dans le cadre de notre « Expert Access » sur l’ASCO 2024 avec un focus sur les développement early stage dans les tumeurs solides. Son intervention a permis de confirmer que l’immunothérapie et la chimiothérapie restaient le « backbone » thérapeutique dans la prise en charge des cancers...
- Dominic Rose
- Naresh Chouhan
Thematic Research - Quantifying The Impact From Part D Reform
In 2025, Big Pharma will be exposed to further US drug pricing reform as a result of the IRA act. This is the final big change to play out and we calculate there is the potential for a mid-single digit EBIT impact for some companies, but there is material heterogeneity in terms of the magnitude of the impact. There is also the potential for upside for Novo & LLY. However, given the significant complexity in the reimburse-ment changes & in computing the current sales in Medicare Part D, we are re...
- Dominic Rose
- Naresh Chouhan
GSK - Downgrade to HOLD (TP £17.50 [£19], 7pgs)
We downgrade GSK to HOLD given the higher risk following the outcome of yesterday’s Delaware trial & the higher payout that GSK could now face. We now assume GSK pays £4bn ($100k/case) and we add a 5% uncertainty discount. Given it will be c.12mths before an appeal decision & a lack of near-term catalysts, we now see limited reasons to own the stock. The Blenrep uptake & Arexvy sales will not become visible until early Q4 and the Depe’ full P3 data is unlikely to drive ST upgrades. Our forecasts...
- Mark Thomas
- Martin Hall
The Hardman & Co Monthly: June 2024
Feature article: Two worlds divided by a common language Summary Few people would deny that raising capital in 2023 and 2024 has been very challenging. The key components of the market, the “two worlds” of corporates and investors, are nowadays often far apart in how they assess value – pre-COVID, this was much less of an issue. This has resulted in frustration and inertia, which, on a sustained basis, can have a significant negative impact on companies and the economy. This issue needs urgen...
- Team Pharma
ODDO : AstraZeneca lives up to expectations at ASCO 2024
>Spotlight on AstraZeneca over the weekend at ASCO 2024 - The ASCO 2024 meeting began last Friday 31 May and will end tomorrow. This morning, we are issuing a recap on the three main results presented by AZN over the weekend.DESTINY-Breast06 should enable the group to gain one line of treatment indication, with Enhertu in advanced hormone positive (ER+ and/or PR+) but HER2 negative (low HER2) breast cancer. These phase III results show a significant clinical redu...
- Team Pharma
ODDO : AstraZeneca répond aux attentes lors de l’ASCO 2024
>AstraZeneca était à l’honneur durant le week-end de l’ASCO 2024 - Le congrès de l’ASCO 2024 a débuté ce vendredi 31 mai pour se terminer demain. Nous revenons notamment ce matin sur les 3 principaux résultats présentés par AZN durant ce week-end :DESTINY-Breast06 devrait permettre d’avancer d’une ligne de traitement l’indication Enhertu dans le cancer du sein avancé hormonopositif (ER+ et/ou PR+) mais HER2 négatif (faible taux de HER2). Ces résultats de phase 3 ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were presented at ASCO 2024, where Immunocore also presented Phase 1 data from its PRAME trial with brenetafusp (IMC-F106C) in advanced cutaneous melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, U...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy brenetafusp (IMC-F106C) in late-line cutaneous melanoma demonstrated promising disease control (partial response and stable disease), progression free survival (PFS), and ctDNA molecular response Clinical activity was ...
Immunocore to present at the Jefferies Global Healthcare Conference
Immunocore to present at the Jefferies Global Healthcare Conference Immunocore to present at the Jefferies Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 30 May 2024) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the Jefferies Global Healthcare Conference. Jefferies Global Healthcare Conference Fireside Chat: Thursday, June 6, ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.